Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
May 7, 2025
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients. This investigation presents a critical opportunity to examine the intricacies of biotechnology supply chains and chart a path forward that strengthens national resilience while keeping the United States at the forefront of scientific innovation.
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory-based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients. This investigation presents a critical opportunity to examine the intricacies of biotechnology supply chains and chart a path forward that strengthens national resilience while keeping the United States at the forefront of scientific innovation.